Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes

Journal of Diabetes Investigation

Volumn 4, Issue 5, 2013, Pages 466-474

  Son, Jang Won ^a   Kim, Dong Jun ^d   Lee, Chang Beom ^e   Oh, Seungjoon ^f   Song, Kee Ho ^g   Jung, Chan Hee ^b   Mok, Ji Oh ^b   Kim, Jong Hwa ^c   Moon, Min Kyong ^h   Choi, Kyung Mook ⁱ   Cho, Jae Hyoung ^j   Choi, Sung Hee ^l   Kim, Soo Kyung ^m   Park, Kang Seo ^k   Kim, Hye Soon ⁿ   Kim, In Joo ^o   Kim, Young Il ^p   Kim, Hae Jin ^q   Kim, Sang Yong ^r   Kim, Sungrae ^a  

^a The Catholic University of Korea   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Sejong General Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Hanyang University Guri Hospital   (South Korea)

^f Kyung Hee University College of Medicine   (South Korea)

^g Konkuk University School of Medicine   (South Korea)

^h Seoul National University Boramae Hospital   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j The Catholic University of Korea   (South Korea)

^k Eulji University   (South Korea)

^l Seoul National University Bundang Hospital   (South Korea)

^m CHA University   (South Korea)

ⁿ Dongsan Medical Center   (South Korea)

^o Pusan National University School of Medicine   (South Korea)

^p University of Ulsan College of Medicine   (South Korea)

^q Ajou University Medical CentSuwon   (South Korea)

^r Chosun University   (South Korea)

more..

Author keywords

Atorvastatin; Low density lipoprotein cholesterol; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PERSONALIZED MEDICINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84884191654     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12074     Document Type: Article

References (32)

1. de Vegt F, Dekker JM, Stehouwer CD, et al. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 2000; 23: 40-44.
2. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-S63.
4. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
5. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
6. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
7. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-197.
8. Insull W, Kafonek S, Goldner D, et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET investigators. Am J Cardiol 2001; 87: 554-559.
9. Jones PH, McKenney JM, Karalis DG, et al. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 2005; 149: e1.
10. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis 2007; 191: 135-146.
11. McKenney JM, Davidson MH, Saponaro J, et al. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol 2005; 46: 594-599.
12. McVey D, Patel H, Eminton Z, et al. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study. Int J Clin Pract 1999; 53: 509-513.
13. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
14. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69C-77C.
15. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5: 150-159.
16. Chapman MJ, Guérin M, Bruckert E.Atherogenic, dense low-density lipoproteins Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19 Suppl A: A24-A30.
17. Cominacini L, Garbin U, Pastorino AM, et al. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 1994; 26: 173-184.
18. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737.
19. Young SG, Parthasarathy S. Why are low-density lipoproteins atherogenic? West J Med 1994; 160: 153-164.
20. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-940.
21. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1417-1424.
22. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539.
23. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112.
24. Nigon F, Lesnik P, Rouis M, et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32: 1741-1753.
25. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17: 3542-3556.
26. Farsang C, Athyros V, Gaw A. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin 2007; 23: 1945-1956.
27. O'Keefe JH Jr, Captain BK, Jones PG, et al. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol 2004; 7: 154-160.
28. Pontrelli L, Parris W, Adeli K, et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51: 334-342.
29. Gensini GF, Gori AM, Dilaghi B, et al. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Int J Cardiol 2010; 142: 257-264.
30. Nakamura T, Kodama Y, Takano H, et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007; 193: 449-451.
31. von Eynatten M, Liu D, Bluemm A, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009; 71: 27-32.
32. Blanco-Colio LM, Martin-Ventura JL, Gómez-Guerrero C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 2008; 586: 259-265.